Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 15, 2016

Primary Completion Date

May 26, 2019

Study Completion Date

December 31, 2019

Conditions
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaLymphoma
Interventions
COMBINATION_PRODUCT

Drugs and Anti-CD19-CAR transduced T cells

"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."

Trial Locations (1)

523059

Department of Hematology, Dongguan People's Hospital, Dongguan

All Listed Sponsors
collaborator

Dongguan People's Hospital

OTHER_GOV

lead

Shenzhen Institute for Innovation and Translational Medicine

OTHER

NCT03076437 - Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | Biotech Hunter | Biotech Hunter